Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Syndax Pharma (NQ: SNDX ) 18.82 +0.13 (+0.70%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Syndax Pharma < Previous 1 2 3 4 Next > Syndax-Incyte Partnered Chronic Graft-Versus-Host Disease Achieves Primary Endpoint In Pivotal Trial, FDA Submission Planned By 2023 End July 24, 2023 Syndax Pharmaceuticals (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) announced topline data from the AGAVE-201 trial of axatilimab, in adult and pediatric patients with chronic graft-versus-host... Via Benzinga Syndax Pharmaceuticals Set for Potential Breakthrough with Revumenib: Analyst Calls It 'Potentially Best-In-Class' In Competitive Landscape July 11, 2023 Guggenheim Partners initiated coverage on Syndax Pharmaceuticals Inc (NASDAQ: SNDX) with a BUY rating and a Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2023 July 11, 2023 Via Benzinga Syndax Pharmaceuticals Earnings Preview May 05, 2023 Via Benzinga Expert Ratings for Syndax Pharmaceuticals March 01, 2023 Via Benzinga Syndax Pharmaceuticals's Earnings: A Preview February 27, 2023 Via Benzinga Analyst Expectations for Syndax Pharmaceuticals's Future January 31, 2023 Via Benzinga Earnings Scheduled For August 3, 2023 August 03, 2023 Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023 July 27, 2023 Via Benzinga Citigroup Maintains Buy Rating for Syndax Pharmaceuticals: Here's What You Need To Know July 26, 2023 Via Benzinga What 7 Analyst Ratings Have To Say About Syndax Pharmaceuticals July 25, 2023 Via Benzinga Syndax Highlights Durable Remissions For Revumenib In Acute Leukemia Patients November 03, 2022 Via Benzinga Earnings Scheduled For March 1, 2022 March 01, 2022 Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... Via Benzinga Earnings Scheduled For May 8, 2023 May 08, 2023 Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 per share on revenue of $462.26 million. Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023 January 31, 2023 Via Benzinga United Natural Foods, Ollie's Bargain, Smith & Wesson Brands And Some Other Big Stocks Moving Lower On Wednesday December 07, 2022 U.S. stocks traded mostly lower, with the Nasdaq Composite dropping over 60 points on Wednesday. Here are some big stocks recording losses in today’s session. Via Benzinga Earnings Scheduled For February 28, 2023 February 28, 2023 Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter. Via Benzinga Earnings Scheduled For November 3, 2022 November 03, 2022 Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion. Via Benzinga Earnings Preview For Syndax Pharmaceuticals November 02, 2022 Syndax Pharmaceuticals (NASDAQ:SNDX) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that... Via Benzinga Stock Market Rally Rises On Inflation Data; Nvidia, Micron, Tesla, Disney In Focus: Weekly Review August 12, 2022 The major indexes continued to advance, despite some key warnings. Via Investor's Business Daily Amphastar, Syndax Top Second-Quarter Estimates, But Runaway Biotechs At A Standstill August 08, 2022 Amphastar came in well above forecasts, while Syndax had fewer than expected losses. Via Investor's Business Daily 12 Health Care Stocks Moving In Thursday's After-Market Session July 07, 2022 Gainers Via Benzinga Earnings Scheduled For August 8, 2022 August 08, 2022 Companies Reporting Before The Bell • Pyxis Tankers (NASDAQ:PXS) is likely to report earnings for its second quarter. Via Benzinga Syndax Pharmaceuticals Stock Sees RS Rating Rise To 92 June 30, 2022 Syndax Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 80 to 92. Via Investor's Business Daily 12 Health Care Stocks Moving In Friday's After-Market Session April 29, 2022 Gainers Ocular Therapeutix (NASDAQ:OCUL) shares moved upwards by 12.3% to $4.01 during Friday's after-market session. The company's market cap stands at $307.7 million. Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For April 11, 2022 April 11, 2022 Upgrades Via Benzinga Earnings Scheduled For May 9, 2022 May 09, 2022 Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million. Via Benzinga Do Penny Stocks Ever Make Money? Here Are 7 Success Stories April 10, 2022 Penny stocks can make money. Success stories include Advanced Micro Devices, a former penny stock that earned a $3.2 billion net income in 2021. Here are six others. Via InvestorPlace Syndax Pharmaceuticals's Return On Capital Employed Overview March 07, 2022 According to Benzinga Pro, during Q4, Syndax Pharmaceuticals (NASDAQ:SNDX) earned $96.20 million, a 566.1% increase from the preceding quarter. Syndax Pharmaceuticals also posted... Via Benzinga Recap: Syndax Pharmaceuticals Q4 Earnings March 01, 2022 Syndax Pharmaceuticals (NASDAQ:SNDX) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... Via Benzinga < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.